Intravitreal injection (IVI) of drugs for treatment of various macular diseases is now one of the most frequently performed surgical procedures worldwide. As mostly chronic diseases are treated, the indications for treatment often mean a continuous treatment over years with a corresponding effort regarding spatial, personnel and financial resources. The diagnosis and indications for treatment are nowadays mainly made by spectral domain optical coherence tomography (SD-OCT). The ability to clinically assess and evaluate a fluorescence angiography is less practiced, although these are still a component of the indications for intravitreal injections. Therefore, it can happen that despite all diligence patients may receive anti-vascular endothelial growth factor (VEGF) treatment, sometimes permanently, based on a misinterpretation of the macular diagnosis or disease activity and these indications, once made, are rarely questioned or retracted. Therefore, the aim of this manuscript is to point out possible and typical misinterpretations in the indications or continuation of IVI treatment with anti-VEGF by means of case studies and to sensitize for differential diagnoses.
Keyphrases
- vascular endothelial growth factor
- optical coherence tomography
- diabetic retinopathy
- disease activity
- computed tomography
- rheumatoid arthritis
- magnetic resonance imaging
- mesenchymal stem cells
- healthcare
- newly diagnosed
- magnetic resonance
- chronic kidney disease
- end stage renal disease
- single molecule
- ultrasound guided
- replacement therapy
- cell therapy
- chemotherapy induced
- dual energy